Qnovia licenses antimicrobial peptide D8 from University of Virginia

The exclusive worldwide deal expands the clinical-stage pharmaceutical company beyond smoking cessation into antimicrobial resistance, with preclinical work planned to support an investigational new drug application.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.